| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 4th January 2021 | Philip H Coelho | 13,513 | Grant/award etc. | $1.48 | $19,999.24 |
| 22nd December 2020 | Patrick J Mcenany | 7,507 | Payment by withholding | $0.00 | |
| 22nd December 2020 | Charles B O'Keeffe | 1,333 | Exercise of derivative | $0.00 | |
| 22nd December 2020 | Patrick J Mcenany | 30,833 | Exercise of derivative | $0.00 | |
| 22nd December 2020 | Steve Miller | 20,000 | Exercise of derivative | $0.00 | |
| 22nd December 2020 | Philip H Coelho | 1,333 | Exercise of derivative | $0.00 | |
| 22nd December 2020 | Gary Ingenito | 3,668 | Open or private sale | $3.45 | $12,643.60 |
| 22nd December 2020 | Gary Ingenito | 14,666 | Exercise of derivative | $0.00 | |
| 22nd December 2020 | Richard J Daly | 1,333 | Exercise of derivative | $0.00 | |
| 22nd December 2020 | David S Tierney | 1,333 | Exercise of derivative | $0.00 |
Catalyst Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Catalyst Pharmaceuticals is a biopharmaceutical company. The company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL. It is developing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.
Ticker: CPRX
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1369568
Employees: 76
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $115 M (0%)
Inventory, Net: $2 M (-6%)
Assets, Current: $131 M (17%)
Property, Plant and Equipment, Net: $168 Th (-20%)
Assets: $131 M (16%)
Accounts Payable, Current: $6 M (40%)
Accrued Liabilities, Current: $14 M (0%)
Liabilities, Current: $20 M (-16%)
Liabilities: $20 M (-18%)
Common Stock, Value, Issued: $103 Th (0%)
Common Stock, Shares, Issued: $103 M (0%)
Retained Earnings (Accumulated Deficit): $108 M (-15%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 Th (-87%)
Stockholders' Equity (Parent): $111 M (0%)
Liabilities and Equity: $131 M (16%)
Revenue: $30 M (-49%)
Cost of Revenue: $4 M (-50%)
Research and Development: $4 M (-49%)
Operating Income/Loss: $10 M (-50%)
Provision for income taxes: $613 Th (-49%)
EPS (basic): $0.09 (-55%)
EPS (diluted): $0.09 (-52%)
News
Catalyst Pharmaceuticals: Attractive Valuation Has Priced In Risks
30th December 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020